Epidemiological characteristics of hepatitis E and progress in vaccine development
[Background]Hepatitis E(HE),a critical acute infectious disease caused by the HE virus(HEV),casts a long shadow over global public health,with approximately 20 million people falling victim to this infection annually.This staggering incidence highlights the insidious nature of HEV,making it a formidable challenge in the realm of infectious diseases.The deployment of vaccines has emerged as the most efficacious strategy to combat the spread of HE,a fact underscored by the introduction of Hecolin®,the world's first HEV vaccine,in 2012.This vaccine,a product of a collaborative endeavor between Xiamen University and Xiamen Wantai Canghai Biotechnology Co.,Ltd.,marked a watershed moment in the fight against HE,leading to the subsequent development and clinical evaluation of numerous vaccine candidates targeting this pervasive infection.[Progress]The epidemiological landscape of HEV has witnessed notable shifts in recent years,reflecting a complex interplay of factors influencing its global distribution.In developing nations,genotypes HEV-1 and HEV-2 reign supreme,underscoring the endemic nature of these strains and their association with waterborne transmission routes.This contrasts with the epidemiological profile observed in developed countries,where HEV-3 is the predominant genotype,although HEV-4 is also present,albeit to a lesser extent.Such distinctions are not merely of academic interest but have profound implications for public health strategies and the design of interventions tailored to the unique challenges presented by the varied genotype prevalence.The intricate interaction between the HEV and its human host is governed by a host of genomic and protein structural characteristics intrinsic to HEV.The virus's genome,with its streamlined architecture,encodes a wealth of information critical for viral assembly,replication,and evasion of the host s immune defenses.The structural elucidation of HEV proteins,particularly those implicated in the virus's capsid and attachment machineries,has paved the way for the rational design of vaccines capable of eliciting potent and protective immune responses.This discussion extends to a critical appraisal of the immunogen design and clinical outcomes of two HEV recombinant vaccines currently navigating the clinical trial landscape,alongside an evaluation of Hecolin®,the pioneering commercial vaccine.The trajectory of these vaccines from bench to bedside encapsulates a saga of scientific discovery,innovation,and rigorous evaluation,underscoring the paramount importance of identifying antigenic constructs that can simulate natural infection without precipitating adverse effects.Such endeavors hinge on a deep understanding of HEV's molecular virology,immunopathology,and the host immune system's intricacies,driving forward the quest for comprehensive protective strategies against HEV.[Perspective]Looking to the future,the need for in-depth research into multiple facets of the HEV epidemic cannot be overstated.Unraveling HEV's global epidemiology,coupled with detailed investigations into the virus's receptors,pathogenic mechanisms,and the manifold interactions with its host,is indispensable for crafting effective prevention and control measures.Furthermore,exploring the health economic benefits of HEV vaccines transcends mere academic inquiry,offering pivotal insights that can guide policy formulation,vaccine deployment strategies,and ultimately,the delivery of cost-effective public health interventions.The confluence of such endeavors promises to usher in a new epoch in the battle against HEV,characterized by enhanced scientific understanding,improved vaccine technologies,and more refined public health strategies.Deciphering the enigma of HEV's biology and epidemiology,and translating these insights into practical,accessible,and affordable vaccines,will constitute fundamental milestones in mitigating the burden of this disease.Within this context,the potential for a new generation of HEV vaccines emerges,fueled by innovation,committed research,and a global collaborative spirit,aiming to consign HEV to the annals of controlled infectious diseases.
万方数据
维普
